Sometimes the smartest answer isn’t the most technical one. This collection highlights ingenious fixes that cut through ...

The Seattle Seahawks and Los Angeles Rams faced off in a crucial game for NFC West supremacy on Thursday night, and the game featured one of the weirdest scoring plays of the year. Seattle was down ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

Sam Altman and Jony Ive have moved their screenless, pocketable AI hardware from concept to prototype, expecting a debut in less than two years The “third core device” is designed around ambient ...

Covering the video games industry since 2017, with experience in news, articles, lists, and reviews (and I blame The Legend of Zelda: Majora's Mask for that). If you are a fan of RPGs and want a third ...

The trio spent one snap last preseason together before Brown suffered a shoulder injury that would knock him out for most of the 2024 season. Then Rice went down with a season-ending knee injury in ...

A lawyer for the former F.B.I. director said he would accuse the Justice Department of malicious and selective prosecution and contend that a U.S. attorney was illegally appointed. By Charlie Savage ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

When Gene Roddenberry created "Star Trek," he didn't pull it out of a vacuum. Impressed with a real life World War II Navy vessel, the USS Enterprise, Roddenberry modeled the capital ship of Starfleet ...

One of the top-trending securities to start Monday morning, video game developer Take-Two Interactive Software (TTWO) has been on quite a run. In the trailing five sessions, TTWO stock gained 3% while ...

Vanguard Extended Market ETF VXF tracks a total market index that excludes S&P 500 stocks. It’s a misfit in the mid-cap blend category, but it pairs well with a fund that tracks the S&P 500 index to ...